These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 11222869)

  • 1. PBPK modeling of canine inhalation exposures to halogenated hydrocarbons.
    Vinegar A
    Toxicol Sci; 2001 Mar; 60(1):20-7. PubMed ID: 11222869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac sensitization thresholds of halon replacement chemicals predicted in humans by physiologically-based pharmacokinetic modeling.
    Vinegar A; Jepson GW
    Risk Anal; 1996 Aug; 16(4):571-9. PubMed ID: 8819347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Setting safe acute exposure limits for halon replacement chemicals using physiologically based pharmacokinetic modeling.
    Vinegar A; Jepson GW; Cisneros M; Rubenstein R; Brock WJ
    Inhal Toxicol; 2000 Aug; 12(8):751-63. PubMed ID: 10880155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling cardiac sensitization potential of humans exposed to Halon 1301 or Halon 1211 aboard aircraft.
    Vinegar A
    Aviat Space Environ Med; 2001 Oct; 72(10):928-36. PubMed ID: 11601558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of desflurane, isoflurane and halothane on regional tissue perfusion in dogs.
    Hartman JC; Pagel PS; Proctor LT; Kampine JP; Schmeling WT; Warltier DC
    Can J Anaesth; 1992 Oct; 39(8):877-87. PubMed ID: 1288912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uptake of anaesthetic gases and vapours.
    Lin CY
    Anaesth Intensive Care; 1994 Aug; 22(4):363-73. PubMed ID: 7978196
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiac sensitization testing of the halon replacement candidates trifluoroiodomethane (CF3I) and 1,1,2,2,3,3,3-heptafluoro-1-iodopropane (C3F7I).
    Dodd DE; Vinegar A
    Drug Chem Toxicol; 1998 May; 21(2):137-49. PubMed ID: 9598296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and respiratory actions of desflurane: is desflurane different from isoflurane?
    Warltier DC; Pagel PS
    Anesth Analg; 1992 Oct; 75(4 Suppl):S17-29; discussion S29-31. PubMed ID: 1524236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac sensitization: methodology and interpretation in risk assessment.
    Brock WJ; Rusch GM; Trochimowicz HJ
    Regul Toxicol Pharmacol; 2003 Aug; 38(1):78-90. PubMed ID: 12878057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rat to human extrapolation of HCFC-123 kinetics deduced from halothane kinetics: a corollary approach to physiologically based pharmacokinetic modeling.
    Williams RJ; Vinegar A; McDougal JN; Jarabek AM; Fisher JW
    Fundam Appl Toxicol; 1996 Mar; 30(1):55-66. PubMed ID: 8812223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of acute dynamic ventilation changes into a standardized physiologically based pharmacokinetic model.
    Ng LJ; Stuhmiller LM; Stuhmiller JH
    Inhal Toxicol; 2007 Mar; 19(3):247-63. PubMed ID: 17365028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo 19F nuclear magnetic resonance brain studies of halothane, isoflurane, and desflurane. Rapid elimination and no abundant saturable binding.
    Litt L; Lockhart S; Cohen Y; Yasuda N; Kim F; Freire B; Laster M; Peterson N; Taheri S; Chang LH
    Ann N Y Acad Sci; 1991; 625():707-24. PubMed ID: 2058918
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiac arrhythmias and blood levels associated with inhalation of Halon 1301.
    Mullin LS; Reinhardt CF; Hemingway RE
    Am Ind Hyg Assoc J; 1979 Jul; 40(7):653-8. PubMed ID: 484490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological preconditioning: comparison of desflurane, sevoflurane, isoflurane and halothane in rabbit myocardium.
    Piriou V; Chiari P; Lhuillier F; Bastien O; Loufoua J; Raisky O; David JS; Ovize M; Lehot JJ
    Br J Anaesth; 2002 Sep; 89(3):486-91. PubMed ID: 12402730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desflurane. A review of its pharmacodynamic and pharmacokinetic properties and its efficacy in general anaesthesia.
    Patel SS; Goa KL
    Drugs; 1995 Oct; 50(4):742-67. PubMed ID: 8536556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dependent metabolism of 2,2-dichloro-1,1,1-trifluoroethane: a physiologically based pharmacokinetic model in the male Fischer 344 rat.
    Vinegar A; Williams RJ; Fisher JW; McDougal JN
    Toxicol Appl Pharmacol; 1994 Nov; 129(1):103-13. PubMed ID: 7974482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Critical evaluation of the new inhalational anesthetics desflurane and sevoflurane].
    Scholz J; Tonner PH
    Anaesthesiol Reanim; 1997; 22(1):15-20. PubMed ID: 9172637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desflurane animal and human pharmacology: aspects of kinetics, safety, and MAC.
    Eger EI
    Anesth Analg; 1992 Oct; 75(4 Suppl):S3-7; discussion S8-9. PubMed ID: 1524237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracranial volume/pressure relationship during desflurane anesthesia in dogs: comparison with isoflurane and thiopental/halothane.
    Artru AA
    Anesth Analg; 1994 Oct; 79(4):751-60. PubMed ID: 7943787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of buprenorphine in anesthetized dogs.
    Martinez EA; Hartsfield SM; Melendez LD; Matthews NS; Slater MR
    Am J Vet Res; 1997 Nov; 58(11):1280-4. PubMed ID: 9361893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.